Abstract Haloperidol is a commonly used neuroleptic drug associated with a range of side effects. The aim of the study was to determine in vitro interaction of haloperidol with human serum albumin (HSA) by 19 F magnetic resonance spectroscopy (MRS) at 9.4 Tesla (T). The practical measurement based on fluorine resonance has been proposed to determine drug level in HSA at 37°C.
Introduction
Human serum albumin (HSA) is a protein found in body fluids and blood plasma which binds to drugs and can have a significant impact on their pharmacokinetics (Petitpas et al., 2001) . Moreover, HSA occurs in human body as a single polypeptide chain of 585 amino acids with weight 66.5 kDa (Dugaiczyk et al., 1982) . The protein binds to several water insoluble endogenous compounds such as bilirubin (He and Carter, 1992) , bile acids (Kragh-Hansen, 1990) , and thus facilitates their transport throughout circulation in the body. Therefore, the study of neuroleptic drugs currently is an emerging area of preclinical research. Most of the recent studies have been using analytical assays to map out the number of binding sites on the HSA. This approach uses a variety of the spectroscopic methods such as Ultra Violet (UV) (Sakurai and Tsuchiya, 2006) and electron spin resonance (Hsia et al., 1978) . In order to study the binding of drug to HSA, we examined the effect with haloperidol upon the relaxation of the fluorine atom. Haloperidol, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one, has one fluorine atom in the structure to be attached to the aromatic ring (Fig. 1) . The already reported methods for the determination of haloperidol in body fluids involve the following techniques: reaction with 1,2-naphthoquinone-4-sulphonic acid (Darwish, 2005) , polarography (Ozkan et al., 2003) , proton ( 1 H) magnetic resonance spectroscopy (Bustillo et al., 2008) , spectrophotometry (Askal (1997) , high performance liquid chromatography (HPLC) (Walter et al., 1998) , and gas chromatography with mass spectrometry (GC-MS) (Ulrich et al., 1998) . Recently, the method for determination of haloperidol in human serum was developed while using HPLC with fluorescence detection. Suzuki coupling reaction with a fluorescent arylboronic acid, 4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid (DPA), was employed to convert haloperidol into highly fluorescent compounds (Kishikawa et al., 2006) . However, the use of Magnetic Resonance (MR) technique has advantage because it enables the direct study of haloperidol without prior treatment.
Current analysis of haloperidol indicates that a limit may exist for haloperidol efficacy; values above this limit seem not to provide any supplementary clinical improvement and may even reduce therapeutic effect (Ulrich et al., 1998) . It has been clinically documented that haloperidol causes often extrapyramidal side effects (motor disturbances) including acute dystonic reactions, acathisia syndrom, drug-induced Parkinsonism, bradykinesia, akinesia, tardive dyskinesia symptoms associated with neurotoxic properties of neuroleptic drugs, and malignant syndrome (Cesario, 2008) . The plasma elimination of haloperidol in humans is much slower with time after dosing, and near terminal elimination half-life may be measured in days rather than hours (Hubbard et al., 1987) . Side effects such as parkinsonian symptoms and neuroleptic malignant syndrome may persist for weeks after discontinuation of neuroleptic drugs (Kornhuber and Weller, 1994) . Therefore, after discontinuation of haloperidol, their side effects are still present for a prolonged period. It is not known whether the extended effects of haloperidol in humans are due to the continued presence of drug in brain tissue or to long-lasting drug-induced physiologic changes (Cohen et al., 1992) .
In this study, we applied fluorine-19 magnetic resonance spectroscopy ( 19 F MRS) at 9.4 Tesla (T) MR system as a tool for identification and quantification of haloperidol. The application of non-proton MRS to in vitro and in vivo monitoring of drug has the advantage over standard 1 H MRS.
1 H and 13 C are nuclei which are most often exploited in MR resonance investigations of biomolecules and drugs. However, 1 H and 13 C MRS of biomolecules and drugs are usually complicated and not easy for interpretation due to many proton-proton or carbon-carbon couplings. Of particular interest is 19 F that has MR sensitivity similar to 1 H. 100% natural abundance of 19 F and its high MR sensitivity (81% of 1 H nucleus), make 19 F MR a reliable analytical tool for the study of organofluorine compounds.
19 F MRS is only restricted to the monitoring of the bio-transformation of 19 F containing drugs, as there is no endogenic fluorine compound in living organisms. To date, the only one study on haloperidol (Shamsipur et al., 2007) was the study with the application of 19 F MRS to assay haloperidol in tablets and haloperidol dissolved in HSA with deuterium solution (D 2 O) transferred into in vitro samples as an internal frequency look at 11.7 T. In vitro 19 F MR has been also already used to aid pharmacodynamics and pharmacokinetics of several medically important fluorinated drugs including antineoplastic fluoropyrimidines ). The application of 1 H NMR has been limited because of the large molecular mass of HSA causing signal broadening (Kitamura et al., 2007) . A wide range of chemical shift (300 ppm) of 19 F compounds ensures good separation of signals in different environments. Furthermore, an internal reference enables quantification without the need for the separation or derivatization (Ellis et al., 2000) . Importantly, such 19 F MRS studies translate well into clinical setting as allows non-invasive monitoring of drug metabolism and pharmacokinetics in vivo (MaletMartino et al., 2006) . Taking these aspects together it is important to determine haloperidol blood levels. The use of 19 F MRS in our study was aimed at investigating the interaction of haloperidol with HSA.
Materials and methods

Preparation of samples and 19 F magnetic resonance spectroscopy
Five milligrams of standard haloperidol (Apotex) was used to prepare stock solution in 10 ml of water. Formic acid of analytical grade (Sigma-Aldrich, Oakville, ON) was added dropwise to achieve pH = 3.5 and 60 mg/ml concentration of HSA (Biofluids, Oakville, ON) was prepared in phosphate buffered saline (0.05 M, pH 6.8). Haloperidol solution was dissolved in an appropriate amount of HSA to give final concentration of 1.5, 5, 30, 60, 120, 180, 240, 300, 360, 420 , and 800 lg/ml of haloperidol. The samples were incubated at 37°C for 2 h in order to reach binding equilibrium.
All 19 F MRS measurements were performed using a 9.4 T magnet with bore diameter of 21 cm (Magnex, UK) and TMX console (NRC-IBD, Canada) operating at 376 MHz. Spectra were recorded at a physiological temperature of 37°C using 5-mm solenoidal probe (NRC-IBD, Canada). Approximately, 10 ml of the sample solution was transferred in an MR glass tube. The 19 F signal of trifluoroacetic acid (TFA) of analytical grade (Sigma-Aldrich, Oakville, ON) with constant concentration in water equal to 1 mg/ml was used as an internal reference for 19 F chemical shift. The signal of TFA was calibrated for chemical shift d = 0.0 ppm. The measured integration of 19 F signal of haloperidol was compared to integration of TFA signal at each haloperidol concentration used. For all samples 19 F MRS was performed using one pulse sequence (flip angle 60°; repetition time (TR) = 800 ms; number of average (NA) = 2 and echo time (TE) = 6 ms). The signal to noises ratio was equal three. The areas of the fluorine resonances in the spectra were analyzed using MAREVISI software (NRC-IBD, Canada). The quantitative measurements were made by measuring ratio of peak areas. Having established the concentration of TFA, the concentration of haloperidol in HSA solution was established from observed 19 F signals. The number of repetitions to reproduce the results was n = 6 for each haloperidol concentration. The accuracy of the 19 F MRS measurements of drug concentration was assessed using two samples with 240 and 420 lg/ml of haloperidol concentration. The starting concentration for both samples was 60 lg/ml of haloperidol. Then the drug was added to obtain the final concentration of 240 and 420 lg/ml, respectively.
The time-stability of the measurements of drug concentration was determined daily by utilizing the coefficient of variation (CV, %) in day first and day third for 1.5, 5, 30, 60, 120, 180, 240, 300, 360, 420, and 800 lg/ml concentrations of haloperidol. Haloperidol binding to HSA has been studied at pH 7.4 and 37°C. The binding equilibrium of drug can be summarized as described in Eq. 1:
where H is haloperidol, HSA is human serum albumin, H-HSA complex of haloperidol and human serum albumin. The constant equilibrium is given as Eq. 2: 
where [H] and [H-HSA] were calculated from integration of fluorine signals in relation to peak area of the TFA. The acquired data are presented as mean ± SD. The calculation was done using Sigma Stat Pro (Chicago, IL).
Results and discussion
Haloperidol solutions alone and solved in HSA were used to obtain spectra at high field MR. Haloperidol itself showed a single signal of its fluorine atom at -29 (d, ppm). The chemical shift of 19 F acquired in haloperidol at concentration of 1.5, 5, 30, 60, 120, 180, 240, 300, 360, 420 , and 800 lg/ml in HSA solution was -9 ± 0.5 (d, ppm).
TFA was selected as an internal standard for spectra due to its sharp 19 F singlet from CF 3 -and was calibrated at 0.0 (d, ppm). Upon the addition of haloperidol solution to HSA, the measured single 19 F signal shifted and broadened. Moreover, the occurred single signal of 19 F in HSA solution indicated that HSA has one binding site for haloperidol, thus the drug together with HSA form a 1:1 complex at each used haloperidol concentrations. We calculated the integral of haloperidol and TFA peaks and took their ratio. Our observations suggest that the detection limit of 19 F of haloperidol was 1.5 lg/ml. The linear regression was used to analyze the data and the correlation coefficient between analytical concentrations take to reaction and measured concentrations on collected 19 F spectra was found to be R 2 = 0.92. 19 F MRS procedure shows to be rapid and selective. The accuracy (in 240 and 420 lg/ml concentration of haloperidol with starting concentration 60 lg/ml) was 91-95%. The time stability of haloperidol concentration in HSA, as determined by the value of the coefficient of variation in day first and day third for each sample was consistently within 4-7%. The fraction of bound of the haloperidol to HSA (p b ) was 0.89 ± 0.2.
One of the novel and most important applications of high field MR in pharmaceutical sciences is its ability to examine protein-drug interactions (Skinner and Laurence, 2008 19 F MR has been already used in clinical studies of mapping fluorine drugs in human brain (Lyoo and Renshaw, 2002) . The result of work in this area is the fact that accumulation of agents in the brain can be much slower than in plasma (Mason and Krystal, 2006 ). In addition, drug level in brain can exceed drug level in plasma (Strauss and Dager, 2001) . Therefore, it is important to provide rapid method to determine plasma level of neuroleptic drugs (Cohen et al., 1980) . In studying the interaction of drugs and proteins, fluorescence techniques are commonly used because of their high sensitivity, rapidity, and ease of implementation. Several reports have been published studying the interaction of proteins with drugs by fluorescence technique (Liu et al., 2004) . However, the multiple binding sites for anesthetics in HSA make solution studies difficult to interpret. The method with UV detection loses sensitivity when extracts of samples are analyzed because of interference caused by the UV-absorbing of many co-extracted compounds. Degradation of the components can also occur in analyzed samples due to the long extraction process. The most suitable compounds for the measurements of 19 F MRS are those containing multiple chemically equivalent fluorine atoms, such as in trifluoromethyl (CF 3 ) groups, due to their high NMR signal per molecule. To date detection of monofluorinated paroxetine in the brain (Henry et al., 2000) was with level of 6 lg/ml. Also the concentrations of the trifluoperazine (Komoroski et al., 1991) and fluphenazine (Durst et al., 1990) were detectable by 19 F MRS in brain at levels 4-5 lg/ml.
In our in vitro study, it was possible to observe 19 F signal in the HSA with detection limit of 1.5 lg/ml. The starting recommended dose of haloperidol for patients is 10 mg/day and the maximum dose is 30 mg/day (Goldman et al., 1981) . Moreover, in human blood plasma with a HSA concentration of about 50-60 mg/ml, haloperidol is approximately 90% bound to the plasma proteins (Kudo and Ishizaki, 1999) .
Recent studies suggest that haloperidol provides rapid therapeutic plasma levels and also can play a role in treating psychiatric emergencies. However, the mean (percent coefficient of variation) haloperidol bioavailability (over 15 min) in plasma after 2.5 mg (2.5 mg/0.1-ml spray) intranasal administration was 63.8 and 48.6% for 2.5 mg (5.0 mg/ml) intramuscular administration (Miller et al., 2008) . Various analytical techniques available to determine drugs concentration in plasma are too time consuming for routine clinical use. The 19 F MRS study shows that the spectroscopy offers quantitative determination of haloperidol in water solution. However, changes in fluorine chemical shifts can be observed when using D 2 O for 19 F MR spectroscopy. The proton-deuterium exchange can influence the fluorine chemical shift (Oldfield et al., 1980) . Therefore, 19 F MRS in an ordinary water solution offers conditions close to that encountered in the real plasma sample. The presented in vitro 19 F MRS method is suitable for measurements of haloperidol in HSA with quantitative accuracy and can be applied to study other fluorine containing drugs. It can be possible that the presented measurement will find the use in the determination of drug pharmacokinetics study or in drug design studies, where binding needs to be optimized.
